A study shows that rising levels of brain protein Aβ42, not the reduction of amyloid plaques, better explains the cognitive benefits of new Alzheimer’s drugs. This finding challenges the traditional focus on plaques in Alzheimer’s treatment. A new study reveals that the rise in protein levels due…